#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Validation of the Czech version of the questionnaire evaluating the early detection of intestinal and extraintestinal manifestations in patients with axial spondyloarthritis at risk of developing idiopathic intestinal inflammation: IBD screening criteria for patients with SpA


Authors: L. Ondrejčáková 1;  M. Gregová 1;  M. Tomčík 1;  J. Hořínková 1;  B. Heřmánková 2;  A. Pekáčová 1;  K. Pavelka 1
Authors‘ workplace: Revmatologický ústav, Revmatologická klinika 1. LF UK, Praha 1;  Katedra fyzioterapie, Fakulta tělesné výchovy a sportu UK, Praha 2
Published in: Čes. Revmatol., 30, 2022, No. 4, p. 148-156.
Category:

Overview

Questionnaires are a simple psychometric tool to assess the subjective ailments of patients with chronic rheumatic diseases. Concerning the late diagnosis of inflammatory bowel disease (IBD) in patients with spondyloarthritis (SpA), a questionnaire was created in the form of screening criteria evaluating intestinal and extraintestinal problems over time. The aim of this work was the Czech translation and its linguistic validation, which consisted of several phases. In the first phase, an independent translation of the original English version into the Czech language was performed, and these versions were analyzed and discussed by the author group through a process of consensus synthesis. In the second phase, the back translation of the unified Czech version of the questionnaire was carried out. In this way, a pre-final version of the questionnaire was created, which was completed by a total of 68 patients suffering from axial SpA, of which 39 patients with non-radiographic axial SpA (nr-AxSpA) and 29 patients with ankylosing spondylitis (AS). A separate part consisted of a feedback questionnaire to evaluate the content, linguistic and stylistic aspects. The comments raised were included in the final Czech version of the questionnaire. In this work, we present the Czech version of the IBD Screening Questionnaire intended for patients with SpA. An official translation will thus enable its common use in both clinical and research fields.

Keywords:

questionnaire – inflammatory bowel disease – validation – axial spondyloarthritis


Sources

1. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017; 390(10089): 73–84.

2. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011; 377(9783): 2127–2137.

3. Stolwijk C, Essers I, van Tubergen A, Boonen A, Bazelier MT, De Bruin ML, et al. The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis 2015; 74(7): 1373–1378.

4. de Winter JJ, van Mens LJ, van der Heijde D, Landewé R, Baeten DL. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther 2016; 18(1): 196.

5. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68(6): 777–783.

6. Peluso R, Di Minno MN, Iervolino S, Manguso F, Tramontano G, Ambrosino P, et al. Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Dev Immunol 2013; 2013: 631408.

7. Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T. Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. World J Gastroenterol 2019; 25(18): 2162–2176.

8. Garrido-Cumbrera M, Navarro-Compán V, Bundy C, Mahapatra R, Makri S, Correa-Fernández J, et al. Identifying parameters associated with delayed diagnosis in axial spondyloarthritis: data from the European map of axial spondyloarthritis. Rheumatology (Oxford) 2022; 61(2): 705–712.

9. Lim CSE, Tremelling M, Hamilton L, Kim M, Mac Gregor A, Turmezei T, Gaffney K. Prevalence of undiagnosed axial spondyloarthritis in inflammatory bowel disease patients with chronic back pain: secondary care cross-sectional study. Rheumatology (Oxford) Aug 22: keac473. doi: 10.1093/rheumatology/keac473. Epub ahead of print. PMID: 35993905. 

10. de Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996; 110(6): 1696–1703.

11. Gilis E, Mortier C, Venken K, Debusschere K, Vereecke L, Elewaut D. The Role of the Microbiome in Gut and Joint Inflammation in Psoriatic Arthritis and Spondyloarthritis. J Rheumatol Suppl 2018; 94: 36–39.

12. Salvarani C, Fries W. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol 2009; 15(20): 2449–2455.

13. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 12(30): 4819–4831.

14. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003; 23(2): 61–66.

15. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017; 76(6): 978–991.

16. Sanz Sanz J, Juanola Roura X, Seoane-Mato D, Montoro M, Gomollón F. Screening of Inflammatory Bowel Disease and Spondyloarthritis for Referring Patients Between Rheumatology and Gastroenterology. Gastroenterol Hepatol 2018; 41(1): 54–62.

17. Raychaudhuri SP, Wilken R, Sukhov AC, Raychaudhuri SK, Maverakis E. Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. J Autoimmun 2017; 76: 21–37.

18. di Carlo M, Luchetti MM, Benfaremo D, Di Donato E, Mosca P, Maltoni S, et al. The DETection of Arthritis in Inflammatory boweL diseases (DETAIL) questionnaire: development and preliminary testing of a new tool to screen patients with inflammatory bowel disease for the presence of spondyloarthritis. Clin Rheumatol 2018; 37(4): 1037–1044.

19. Stebbings S, Jenks K, Treharne GJ, García JA, Schultz M, Highton J, et al. Validation of the Dudley Inflammatory Bowel Symptom Questionnaire for the assessment of bowel symptoms in axial SpA: prevalence of clinically relevant bowel symptoms and association with disease activity. Rheumatology (Oxford) 2012; 51(5): 858–865.

20. Battat R, Kopylov U, Szilagyi A, Saxena A, Rosenblatt DS, Warner M, et al. Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management. Inflamm Bowel Dis 2014; 20(6): 1120–1128.

21. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) 2000; 25(24): 3186–3191.

22. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27(4): 361–368.

23. Prajzlerová K, Grobelná K, Pavelka K, Šenolt L, Filková M. An update on biomarkers in axial spondyloarthritis. Autoimmun Rev 2016; 15(6): 501–509.

24. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker- Hermann E, Zeidler H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70(8): 1369–1374.

25. Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014; 73(1): 39–47.

26. Bubová K, Forejtová Š, Zegzulková K, Gregová M, Hušáková M, Filková M, et al. Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort. BMJ Open 2019; 9(4): e024713.

27. Sharma SM, Jackson D. Uveitis and spondyloarthropathies. Best Pract Res Clin Rheumatol 2017; 31(6): 846–862.

28. Sorrentino D. Preclinical and Undiagnosed Crohn’s Disease: The Submerged Iceberg. Inflamm Bowel Dis 2016; 22(2): 476–486.

29. Seo MR, Baek HL, Yoon HH, Ryu HJ, Choi HJ, Baek HJ, et al. Delayed diagnosis is linked to worse outcomes and unfavourable treatment responses in patients with axial spondyloarthritis. Clin Rheumatol 2015; 34(8): 1397–1405.

30. Robinson PC, Brown MA. The window of opportunity: a relevant concept for axial spondyloarthritis. Arthritis Res Ther 2014; 16(3): 109.

31. Ibáñez Vodnizza SE, de La Fuente MPP, Parra Cancino EC. Approach to the Patient with Axial Spondyloarthritis and Suspected Inflammatory Bowel Disease. Rheum Dis Clin North Am 2020; 46(2): 275–286.

32. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol 2014; 6: 71–80.

33. Abdul Rani R, Raja Ali RA, Lee YY. Irritable bowel syndrome and inflammatory bowel disease overlap syndrome: pieces of the puzzle are falling into place. Intest Res 2016; 14(4): 297–304.

34. Wallman JK, Mogard E, Marsal J, Andréasson K, Jöud A, Geijer M, et al. Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity? Ann Rheum Dis 2020; 79(1): 159–161.

35. Cypers H, Varkas G, Beeckman S, Debusschere K, Vogl T, Roth J, et al. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis 2016; 75(7): 1357–1362.

36. Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess 2013; 17(55): xv–xix, 1–211.

Labels
Dermatology & STDs Paediatric rheumatology Rheumatology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#